1524. Are Providers Shifting from NTF to Fosfomycin for Inpatient UTI? Big Data Reveals Small Shifts
Kalpana Gupta, MPH1; Matthew B. Goetz, MD1; Makoto Jones, MD, MS2; and Judith M. Strymish, MD3;1: VA Healthcare System, West Roxbury, MA, 2Boston University School of Medicine, Boston, Massachusetts, 3David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, 4Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, 5Ideas Center, VA Salt Lake City Health Care System, Salt Lake City, Utah, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah and 6VA Healthcare System, West Roxbury, MA, 7Harvard Medical School, Boston, Massachusetts
Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Fosfomycin (FOS) and NTF (NTF) are IDSA guideline approved drugs for acute cystitis in women. However, their activity against multi drug-resistant Gram-negatives may be driving increased use among inpatients with more complicated UTI. We evaluated trends in inpatient prescribing of these UTI-specific agents in the predominantly male population of the national VA system over a 7-year period.

Methods. All inpatient bar coded administrations for FOS and NTF at every VA facility nationwide from 2011 to 2017 were captured through a data analytics platform which extracts data from the VA Data Warehouse. Antibiotic days of therapy and rates per 1,000 patient-days (DOT/1,000CD) were extracted by year and compared using Mantel Haenszel chi square for linear trend (MH OR). Demographics were captured via administrative data.

Results. Prescriptions from over 65 million patient-days spanning 7 years and all inpatient units in 129 VA facilities were included. Approximately 90% of patients were male with a mean age range of 55-64 years. FOS use increased from 128 prescriptions in 2011 to a high of 1,230 in 2016 and 1,003 in 2017 (figure). At the maximum in 2016, prescription rates increased almost 10-fold compared with 2011 (MH OR 9.8, P < 0.001). NTF prescriptions declined from 26,590 in 2011 to 19,343 in 2017. Rates decreased 25% from 2.8 to 2.1, MH OR 0.75, P < 0.001. In 2017, FOS and NTF usage rates were highest in rehabilitation/spinal cord units (table).

Conclusion. In this large nationwide cohort, FOS use increased almost 10-fold among predominantly male inpatients while NTF use declined slightly. NTF is still used orders of magnitude more than FOS, even after adjusting for extended days of activity of FOS. Both agents retain activity against many MDR GNRs but differences in efficacy, tissue penetration, familiarity and availability likely influence the choice for oral UTI-specific treatment.

2017 Data  
| DOT1/1,000CD | ICU | MEDSURG | NH | PSYCH | REHAB/SCI |
|-------------|-----|---------|----|-------|----------|
| FOS         | 0.06| 0.15    | 0.07| 0.03  | 0.73     |
| NTF         | 0.56| 1.46    | 2.41| 2.55  | 9.35     |
| FOS days    | 28  | 389     | 292 | 25    | 28       |
| NTF days    | 251 | 3,699   | 7,026| 2,634| 4,013    |

Disclosures. All authors: No reported disclosures.

1525. Evaluation of Clinical Outcomes With Fosfomycin for E. coli and Non-E. coli Enterobacteriaceae Urinary Tract Infections
Tiffany Lee, PharmD1; Lauret Glaser, MD, PhD1; and Kevin Alby, PhD2; 1Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 2Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Fosfomycin is a broad-spectrum oral antibiotic increasingly used for the treatment of uncomplicated and complicated urinary tract infections (UTIs). The Clinical and Laboratory Standards Institute (CLSI) does not support fosfomycin susceptibility testing on urinary isolates outside of Enterococcus faecalis and Escherichia coli. This is in light of building evidence and concern for the presence of chromosomal fmo gene in non-E. coli Enterobacteriaceae. Regardless, clinicians have continued to test and use fosfomycin for these pathogens due to multidrug resistance or intolerance to other agents without ample data on clinical implications.

Methods. This retrospective study included patients who received fosfomycin for the treatment of a UTI caused by any Enterobacteriaceae for which fosfomycin testing was performed from March 2016 through April 2018. We separated patients who received fosfomycin for the treatment of UTIs caused by E. coli from those caused by other Enterobacteriaceae for comparison. The primary outcome is the rate of clinical success at 48 hours, defined as the absence of UTI symptoms and normalization of vital signs. The secondary outcome is the rate of recurrent UTIs caused by the same pathogen within 30 days of the index infection.

Results. There were 28 separate episodes of E. coli UTIs in 24 patients and 25 separate episodes of non-E. coli UTIs in 26 patients included in this study. Patients were mostly balanced between the two groups and were on average about 64 years old, mostly females (61%), and had an average Charlson Comorbidity Index of 5. All E. coli isolates were susceptible to fosfomycin, while only 82.8% non-E. coli isolates were fosfomycin-susceptible. The rates of clinical success were similar between the E. coli and non-E. coli patients (89.3% vs. 88.5%). There was a higher rate of recurrence of the same UTI with E. coli (15.4%) than with non-E. coli (4.8%).

Conclusion. Findings from this small study suggest favorable outcomes with use of fosfomycin for non-E. coli Enterobacteriaceae. Despite recommendations against testing and use of fosfomycin in these pathogens, it appears that in vitro resistance does not always correlate with clinical response.

Disclosures. All authors: No reported disclosures.